Design, synthesis and biological evaluation of the positional isomers of the galactose conjugates able to target hepatocellular carcinoma cells via ASGPR-mediated cellular uptake and cytotoxicity

Eur J Med Chem. 2024 Jan 15:264:115988. doi: 10.1016/j.ejmech.2023.115988. Epub 2023 Nov 25.

Abstract

Galactose as a recognizing motif for asialoglycoprotein receptor (ASGPR) is a widely accepted vector to deliver cytotoxic agents in the therapy of hepatocellular carcinoma (HCC), however, the individual hydroxyl group of galactose (Gal) contributed to recognizing ASGPR is obscure and remains largely unanswered in the design of glycoconjugates. Herein, we designed and synthesized five positional isomers of Gal-anthocyanin Cy5.0 conjugates and three Gal-doxorubicin (Dox) isomers, respectively. The fluorescence intensity of Gal-Cy5.0 conjugates accumulated in cancer cells hinted the optimal modification sites of positions C2 and C6. Comparing to the cytotoxicity of other conjugates, C2-Gal-Dox (11) was the most potent. Moreover, Gal-Dox conjugates significantly the toxicity of Dox. A progressively lower internalization capacity and siRNA technology implied the cellular uptake and cytotoxicity directly related to the ASGPR expression level. Accordingly, position C2 of galactose may be the best substitution site via ASGPR mediation in the design of anti-HCC glycoconjugates.

Keywords: ASGPR; Galactose; Glycoconjugates; Hepatocellular carcinoma; Positional isomer.

MeSH terms

  • Asialoglycoprotein Receptor / metabolism
  • Carcinoma, Hepatocellular* / pathology
  • Doxorubicin / pharmacology
  • Galactose
  • Glycoconjugates / pharmacology
  • Humans
  • Liver Neoplasms* / pathology

Substances

  • Galactose
  • Asialoglycoprotein Receptor
  • cyanine dye 5
  • Doxorubicin
  • Glycoconjugates